The prevalence, awareness, treatment and control of dyslipidemia among adults in China

Atherosclerosis

Volumn 248, Issue , 2016, Pages 2-9

  Pan, Ling ^a,b   Yang, Zhenhua ^a,b   Wu, Yue ^a,b   Yin, Rui Xing ^a   Liao, Yunhua ^a,b   Wang, Jinwei ^c,d   Gao, Bixia ^c,d   Zhang, Luxia ^c,d  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

^c PEKING UNIVERSITY FIRST HOSPITAL   (China)

^d PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

China; Dyslipidemia; Epidemiology; Prevalence

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHINESE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; EXERCISE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; INCOME; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBESITY; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RURAL AREA; RURAL POPULATION; URBAN AREA; ADOLESCENT; ATTITUDE TO HEALTH; BLOOD; CHINA; COMPLICATION; DYSLIPIDEMIAS; MULTIVARIATE ANALYSIS; ODDS RATIO; PATHOLOGY; POSTMENOPAUSE; REGRESSION ANALYSIS; RISK FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHINA; CROSS-SECTIONAL STUDIES; DIABETES COMPLICATIONS; DYSLIPIDEMIAS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; HYPERTENSION; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; POSTMENOPAUSE; PREVALENCE; REGRESSION ANALYSIS; RISK FACTORS; TRIGLYCERIDES; YOUNG ADULT;

EID: 84960338304     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2016.02.006     Document Type: Article

References (28)

1. Roger V.L., Go A.S., Lloyd-Jones D.M., et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 2011, 123:e18-e209.
2. Rabar S., Harker M., O'Flynn N., et al. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance. BMJ 2014, 349:g4356.
3. Reiner Z., Catapano A.L., De Backer G., et al. ESC/EAS guidelines for the management of dyslipidaemias. Rev. espanola Cardiol. 2011, 64. 1168 e1161-1168 e1160.
4. Beaglehole R. Global cardiovascular disease prevention: time to get serious. Lancet 2001, 358:661-663.
5. Expert panel on detection, E and treatment of high blood cholesterol in, A, executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
6. Joint Committee for Developing Chinese guidelines on, P and Treatment of Dyslipidemia in, A Chinese guidelines on prevention and treatment of dyslipidemia in adults. Zhonghua xin xue guan bing za zhi 2007, 35:390-419.
7. Pisciotta L., Bertolini S., Pende A. Lipoproteins, stroke and statins. Curr. Vasc. Pharmacol. 2015, 13(2):202-208.
8. Zhao W.H., Zhang J., You Y., et al. Epidemiologic characteristics of dyslipidemia in people aged 18 years and over in China. Zhonghua yu fang yi xue za zhi Chin. J. Prev. Med. 2005, 39:306-310.
9. Zhang L., Wang F., Wang L., et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet 2012, 379:815-822.
10. Toth P.P., Potter D., Ming E.E. Prevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey 2003-2006. J. Clin. Lipidol. 2012, 6:325-330.
11. Wu Y., Huxley R., Li L., et al. Prevalence, awareness, treatment, and control of hypertension in China: data from the China National Nutrition and Health Survey 2002. Circulation 2008, 118:2679-2686.
12. Yang W., Xiao J., Yang Z., et al. Serum lipids and lipoproteins in Chinese men and women. Circulation 2012, 125:2212-2221.
13. Li J.H., Wang L.M., Li Y.C., et al. Epidemiologic characteristics of dyslipidemia in Chinese adults 2010. Zhonghua yu fang yi xue za zhi Chin. J. Prev. Med. 2012, 46:414-418.
14. Feig J.E., Hewing B., Smith J.D., et al. High-density lipoprotein and atherosclerosis regression: evidence from preclinical and clinical studies. Circ. Res. 2014, 114:205-213.
15. van de Woestijne A.P., van der Graaf Y., Liem A.H., et al. Low high-density lipoprotein cholesterol is not a risk factor for recurrent vascular events in patients with vascular disease on intensive lipid-lowering medication. J. Am. Coll. Cardiol. 2013, 62:1834-1841.
16. Sonmez A., Yilmaz M.I., Saglam M., et al. The role of plasma triglyceride/high-density lipoprotein cholesterol ratio to predict cardiovascular outcomes in chronic kidney disease. Lipids Health Dis. 2015, 14:29.
17. Go A.S., Mozaffarian D., Roger V.L., et al. Executive summary: heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 2014, 129:399-410.
18. Hu S.S., Kong L.Z., Gao R.L., et al. Outline of the report on cardiovascular disease in China, 2010. Biomed. Environ. Sci. BES 2012, 25:251-256.
19. Zhang X., Patel A., Horibe H., et al. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int. J. Epidemiol. 2003, 32:563-572.
20. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J. Am. Coll. Cardiol. 2004, 44:720-732.
21. Rosamond W., Flegal K., Furie K., et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008, 117:e25-146.
22. Ford E.S., Capewell S. Coronary heart disease mortality among young adults in the U.S. from 1980 through 2002: concealed leveling of mortality rates. J. Am. Coll. Cardiol. 2007, 50:2128-2132.
23. Li J.H., Wang L.M., Mi S.Q., et al. Awareness rate, treatment rate and control rate of dyslipidemia in Chinese adults, 2010. Zhonghua yu fang yi xue za zhi Chin. J. Prev. Med. 2012, 46:687-691.
24. Wang F., Ye P., Hu D., et al. Lipid-lowering therapy and lipid goal attainment in patients with metabolic syndrome in China: subgroup analysis of the Dyslipidemia International Study-China (DYSIS-China). Atherosclerosis 2014, 237:99-105.
25. Jellinger P.S., Smith D.A., Mehta A.E., et al. American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr. Pract. Off. J. Am. Coll. Endocrinol. Am. Assoc. Clin. Endocrinol. 2012, 18(Suppl. 1):1-78.
26. Wakatsuki A. Hormone replacement Up-to-date. Effects of estrogen replacement therapy on lipid metabolism. Clin. Calcium 2007, 17:1366-1371.
27. Utian W.H., Archer D.F., Bachmann G.A., et al. Estrogen and Progestogen Use in Postmenopausal Women: July 2008 Position Statement of the North American Menopause Society, Menopause (New York, N.Y.) 2008, vol. 15:584-602.
28. Wang S., Xu L., Jonas J.B., et al. Prevalence and associated factors of dyslipidemia in the adult Chinese population. PLoS One 2011, 6:e17326.